2023 年 8 月 18 日，公司接到桐梓化工通知，桐梓化工合成氨液 氮洗设备及尿素装置已完成检修，合成氨-尿素生产线已于 8 月 15 日 恢复开车，8 月 17 日下午产出合格的尿素产品，目前生产生常，装 置运行稳定。 证券代码：600227 证券简称：赤 天 化 编号：2023-051 贵州赤天化股份有限公司 关于全资子公司桐梓化工完成部分生产装置检修并 恢复生产的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 8 月 3 日，公司发布了《贵州赤天化股份有限公司关于 全资子公司桐梓化工部分生产装置停车检修的公告》（公告编号： 2023-050），为了保证生产线安全、有效运行，经公司研究决定对贵 州赤天化桐梓化工有限公司（以下简称"桐梓化工"）合成氨液氮洗 设备及尿素装置进行检修，预计检修时间为 16 天。现将有关进展情 况公告如下： 经财务部门初步测算，桐梓化工本次部分生产装置停车检修不影 响公司年度产量计划的完成。桐梓化工本次对合成氨液氮洗设备及尿 素装置进行检修，预计产生停车损失约 1,032 ...

证券代码：600227 证券简称：圣 济 堂 编号：2023－031 贵州圣济堂医药产业股份有限公司 关于参加"2022 年度贵州辖区上市公司业绩说明会 暨投资者集体接待日活动"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 活动召开时间：2023 年 5 月 17 日（周三）下午 15:30-17:30 活动召开地点："全景路演"（网址：http://rs.p5w.net） 活动召开方式："全景路演"网络远程方式，投资者可在上述 召开时间，通过"全景路演"（网址：http://rs.p5w.net），在线 参与本次活动，公司将及时回答投资者的提问。 投资者可于本公告发出之日起至 2023 年 5 月 15 日，通过微信 关注"贵州资本市场"公众号，发送关键词"提问"，进入专区提前 提交问题。公司将在本次说明会上对投资者普遍关注的问题进行回 答。 贵州圣济堂医药产业股份有限公司（以下简称"公司"）已 于 2023 年 4 月 26 日 在 上 海 证 券 交 易 所 网 站 （http://www.ss ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥495,668,175.06, representing a decrease of 13.97% compared to the same period last year[5]. - The net profit attributable to shareholders of the listed company was a loss of ¥34,708,006.89, with no applicable percentage change due to the nature of the loss[5]. - The net profit for Q1 2023 was -¥9,663,627.67, an improvement from -¥13,889,564.74 in Q1 2022, indicating a reduction in losses[28]. - The company reported a net loss of CNY 1,823,250,207.87 for Q1 2023, compared to a net loss of CNY 1,788,542,200.98 in Q1 2022[16]. - The company incurred a total comprehensive loss of -41,348,153.15 RMB in Q1 2023, compared to -88,044,099.99 RMB in Q1 2022[19]. - Operating profit for Q1 2023 was -40,876,846.46 RMB, an improvement from -86,237,309.56 RMB in the same period last year[19]. Cash Flow and Liquidity - The net cash flow from operating activities was a negative ¥49,488,943.71, indicating a decrease in cash received from sales and services[6]. - Cash flow from operating activities for Q1 2023 was ¥51,237,580.35, an increase from ¥35,984,060.45 in Q1 2022, showing improved cash generation[29]. - Cash and cash equivalents increased to CNY 148,344,651.20 as of March 31, 2023, compared to CNY 94,557,360.29 at the end of 2022, representing a growth of 57.0%[13]. - The cash outflow for investment activities in Q1 2023 was -¥36,400,000.00, indicating ongoing investments despite previous losses[29]. - The net cash flow from financing activities in Q1 2023 was 136,837,180.56 RMB, compared to 162,654,079.22 RMB in Q1 2022[23]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,545,694,300.30, down 1.54% from the end of the previous year[6]. - Total liabilities decreased to CNY 1,801,365,530.91 from CNY 1,817,864,028.85 at the end of 2022, a reduction of 0.9%[15]. - The total assets as of Q1 2023 amounted to ¥2,961,032,741.96, a decrease from ¥3,052,497,124.63 in the previous year[26]. - The total liabilities for Q1 2023 were ¥246,837,273.65, down from ¥323,218,602.53 in Q1 2022, reflecting a reduction in financial obligations[26]. Shareholder Equity - The equity attributable to shareholders of the listed company decreased by 1.41% to ¥2,759,221,905.47 compared to the end of the previous year[6]. - The total equity attributable to shareholders was CNY 2,759,221,905.47 as of March 31, 2023, down from CNY 2,798,754,984.21 at the end of 2022[16]. - The total equity as of Q1 2023 was ¥2,714,195,468.31, slightly down from ¥2,729,278,522.10 in the previous year, reflecting stability in shareholder value[26]. Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 505,239,641.67, down 22.1% from CNY 649,054,625.74 in Q1 2022[18]. - Research and development expenses decreased to CNY 13,131,988.47 in Q1 2023, a reduction of 65.6% compared to CNY 38,180,899.23 in Q1 2022[18]. - The company reported a significant decrease in financial expenses, with Q1 2023 at ¥791,768.69 compared to ¥2,796,223.08 in Q1 2022, indicating better cost management[28]. Revenue Sources - The decrease in operating revenue was primarily due to the suspension of methanol production, resulting in no sales revenue from methanol during the reporting period[8]. - Total revenue from sales and services received in Q1 2023 was 441,388,329.01 RMB, down from 651,084,204.26 RMB in Q1 2022, representing a decrease of approximately 32.2%[22]. - The company reported non-operating income of ¥787,216.83, which includes government subsidies closely related to normal business operations[8]. Strategic Initiatives - The company plans to focus on new product development and market expansion as part of its strategic initiatives moving forward[28].

Financial Performance - The company's operating revenue for 2022 was ¥2,517,340,257.45, representing a 15.40% increase compared to ¥2,181,369,746.32 in 2021[23]. - The revenue from core business activities, after excluding non-core income, was ¥2,456,807,313.84, which is an 18.39% increase from ¥2,075,212,366.58 in the previous year[23]. - The net profit attributable to shareholders was -366.57 million RMB, compared to -51.87 million RMB in the previous year, indicating a significant increase in losses[24]. - The basic earnings per share decreased to -0.2165 RMB from -0.0306 RMB in 2021, reflecting a worsening financial performance[25]. - The weighted average return on equity dropped to -12.29%, a decrease of 10.67 percentage points compared to the previous year[25]. - The company's total assets at the end of 2022 were 4,616.63 million RMB, a slight increase of 0.31% from 2021[24]. - The cash flow from operating activities was 195.62 million RMB, down 29.30% from the previous year[24]. - The company reported a total revenue of -151.39 million yuan and a net loss of -182.77 million yuan, marking a shift from profit to loss compared to the previous year[35]. - The company's net assets attributable to shareholders decreased by 11.58% to 2,798.75 million RMB compared to the end of 2021[24]. Business Segments - The chemical business segment achieved revenue of 2,392.54 million RMB, a year-on-year increase of 17.08%, while the cost of goods sold rose by 36.92%[34]. - The pharmaceutical manufacturing segment experienced a decline in sales volume and revenue by 22.53% and 9.47%, respectively, due to regulatory impacts[34]. - The pharmaceutical segment generated revenue of 124.80 million yuan, a decrease of 9.53% year-on-year, with a net loss of -188.71 million yuan, exacerbated by the cancellation of procurement qualifications for key products[42]. - The company’s chemical business, primarily through its subsidiary Tongzi Chemical, has a designed capacity of 520,000 tons of urea and 300,000 tons of methanol annually[87]. - The company’s compound fertilizer sales revenue increased by 269.29% year-on-year, with a gross margin of 8.26%[172]. Market Conditions - The domestic urea market saw a price increase of 12.09% year-on-year, with an average price of CNY 2,717 per ton in 2022[52]. - Urea production in 2022 reached 56.3 million tons, a 4.84% increase from 2021, with a capacity utilization rate of 76.33%[53]. - The average price of compound fertilizer in 2022 was 3,521 RMB/ton, reflecting a year-on-year increase of 26.75%[63]. - The average price drop for selected products in the national procurement program exceeded 52%, compelling pharmaceutical companies to upgrade their operational management to maintain market presence[76]. - The market for diabetes medications in China is projected to exceed CNY 11.8 billion, with a growth rate of 11.6%[128]. Research and Development - The company filed 10 patent applications and received 30 patent grants in 2022, indicating a strong commitment to R&D and innovation[39]. - The company reported a total R&D investment of approximately 97.2 million yuan, which is 3.86% of total revenue, with capitalized R&D accounting for 0.52%[113]. - The company is focusing on the R&D of diabetes medications, including the sustained-release form of metformin and other related drugs, with a goal to expand its diabetes product line[188]. - The company has suspended the research and development of certain projects, including the Amber Acid Quge and Azilsartan raw materials, due to loss of competitive advantage and production transfer issues[141]. - The company is currently conducting process verification for Yimucao granules, aimed at treating menstrual disorders[140]. Operational Efficiency - The company completed 25 technical improvement projects in 2022, including 3 major upgrades, which effectively reduced production costs and improved energy efficiency[37]. - The company strengthened its management to improve operational efficiency, focusing on stable supply and cost control, resulting in effective management of raw material supply costs[47]. - The company is positioned as a market leader in the urea sector within Guizhou, leveraging transportation advantages over competitors using natural gas[161]. - The company has implemented energy-saving modifications to existing facilities to enhance resource utilization and align with national low-carbon policies[187]. - The company is focusing on optimizing its management systems across various departments, including administration, medical, and financial management, to enhance operational efficiency[50]. Governance and Compliance - The company has not engaged in any non-operational fund occupation by controlling shareholders or related parties during the reporting period[7]. - The company has not violated any decision-making procedures regarding external guarantees[7]. - The company has a commitment to transparency and has disclosed its annual report through multiple media channels, including the Shanghai Stock Exchange website[19]. - The company has established a complete and independent financial accounting system, ensuring no shared bank accounts with the actual controller or related enterprises[200]. - The company maintains a fully independent operational capability, with no business dependencies or competitive relationships with the actual controller's other enterprises[200]. Challenges and Risks - The company is facing risks that may adversely affect its future development strategies and operational goals, as detailed in the risk analysis section[8]. - The company has identified risks including raw material coal supply, water resource availability, and rising coal prices, which could impact production operations[193]. - The company faces significant challenges due to national "carbon peak" and "carbon neutrality" policies, requiring increased investment in energy efficiency and carbon reduction to avoid being phased out[195]. - The pharmaceutical industry is heavily influenced by government policies, with ongoing risks of product price declines due to healthcare reforms and centralized procurement policies[196]. - The company is developing multiple new drug varieties, but the lengthy and costly R&D process poses risks if market demand is not met, potentially affecting sales and profitability[196].

Financial Performance - The company's operating revenue for Q3 2022 was ¥549,978,912.85, a decrease of 11.75% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥126,965,118.04, with a year-to-date net profit of -¥222,690,490.28[5]. - The basic earnings per share for the current period was -¥0.0750, and the diluted earnings per share was also -¥0.0750[6]. - The net profit for the third quarter of 2022 was a loss of ¥225,155,375.43, compared to a profit of ¥114,983,715.58 in the same quarter of 2021[22]. - The net profit for the first three quarters of 2022 was a loss of ¥38,134,313.54, compared to a loss of ¥26,452,789.39 in the same period of 2021, representing an increase in loss of 43.9%[32]. - The total comprehensive income for the third quarter of 2022 was -¥224,510,357.51, compared to ¥113,055,024.46 in the same quarter of 2021[23]. - The company reported a total comprehensive loss of ¥37,489,295.62 for the first three quarters of 2022, compared to a loss of ¥28,381,480.51 in the same period of 2021, reflecting a worsening financial position[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,652,054,741.19, reflecting a 1.08% increase from the end of the previous year[6]. - The total liabilities as of the third quarter of 2022 amounted to ¥1,706,273,886.21, compared to ¥1,432,117,778.16 in the previous year, indicating a growth of 19.1%[19]. - The total equity attributable to shareholders decreased to ¥2,943,324,885.52 from ¥3,165,129,156.69 year-over-year, a decline of 7.0%[19]. - The total assets as of September 30, 2022, amounted to 3,103,979,723.42 RMB, down from 3,173,899,518.09 RMB at the end of 2021[29]. - The total liabilities decreased to 337,730,708.21 RMB from 370,161,207.26 RMB in the previous year[30]. - The total equity as of September 30, 2022, was 2,766,249,015.21 RMB, compared to 2,803,738,310.83 RMB at the end of 2021[30]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥161,895,980.62, a decrease of 23.00% compared to the same period last year[5]. - The net cash flow from operating activities was 161,895,980.62 RMB, a decrease from 210,255,212.36 RMB in the previous year[26]. - The net cash flow from investing activities was -383,904,125.18 RMB, compared to -137,352,782.19 RMB in the same period last year[26]. - The net cash flow from financing activities was 209,120,149.83 RMB, a significant improvement from -20,610,550.87 RMB in the previous year[27]. - The cash flow from operating activities for the first three quarters of 2022 was ¥203,661,452.49, an increase of 37.7% compared to ¥147,951,637.28 in the same period of 2021[34]. Operational Changes - The company attributed the decline in net profit to rising raw material costs and the suspension of operations at its wholly-owned subsidiary, Tongzi Chemical[8]. - The company has decided to temporarily suspend methanol production at its wholly-owned subsidiary Tongzi Chemical due to negative profit margins caused by low market prices and rising raw material costs[13]. - The company reported a significant increase in research and development expenses, totaling ¥80,022,914.51 for the first three quarters of 2022, compared to ¥67,310,303.26 in 2021, reflecting a growth of 18.5%[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 56,854[11]. - Guizhou Yuyang Trading Co., Ltd. holds 447,733,355 shares, accounting for 26.4% of total shares[11]. Other Financial Metrics - The weighted average return on equity was -4.22% for the current period, compared to -7.29% year-to-date[6]. - The company experienced a credit impairment loss of ¥91,736,749.35 in the third quarter of 2022, contrasting with a gain of ¥732,205.92 in the same quarter of 2021[22]. - The company's financial expenses increased to ¥15,380,367.04 in the first three quarters of 2022, compared to ¥9,601,197.47 in the same period of 2021, marking a rise of 60.5%[31]. - The company's interest expenses were ¥5,255,332.92 in the first three quarters of 2022, a decrease of 17.3% from ¥6,347,282.53 in the same period of 2021[31].

Financial Performance - The company's operating revenue for the first half of 2022 was approximately CNY 1.38 billion, representing a 33.60% increase compared to CNY 1.03 billion in the same period last year[19]. - The net profit attributable to shareholders of the listed company was a loss of approximately CNY 95.73 million, compared to a profit of CNY 82.18 million in the same period last year[19]. - The net cash flow from operating activities decreased by 10.79% to approximately CNY 197.87 million, down from CNY 221.80 million in the previous year[19]. - The total assets at the end of the reporting period were approximately CNY 4.74 billion, an increase of 3.08% from CNY 4.60 billion at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company decreased by 3.01% to approximately CNY 3.07 billion, down from CNY 3.17 billion at the end of the previous year[19]. - The basic earnings per share for the first half of 2022 was -CNY 0.0565, compared to CNY 0.0485 in the same period last year[20]. - The weighted average return on net assets was -3.07%, a decline from 2.52% in the previous year[20]. - The company reported a loss of approximately CNY 100.84 million after deducting non-recurring gains and losses, compared to a profit of CNY 80.44 million in the same period last year[19]. - The company achieved a total operating revenue of 1.379 billion yuan, with a profit of -106 million yuan[37]. - The overall revenue increased by 347 million yuan, representing a year-on-year growth of 33.60%[37]. - The company reported a net loss of RMB 97,267,590.67 for the first half of 2022, compared to a net profit of RMB 79,609,151.79 in the first half of 2021[140]. - The total profit for the first half of 2022 was RMB -105,634,777.20, compared to RMB 79,969,884.67 in the first half of 2021[140]. Cash Flow and Investments - The net cash flow from investing activities was negative at approximately CNY -265.93 million, a significant increase in cash outflows for fixed and intangible asset purchases[48]. - The net cash flow from financing activities increased by 585.85% year-on-year to approximately CNY 143.91 million, mainly due to increased cash from loans[48]. - Cash and cash equivalents at the end of the period increased by 59.39% year-on-year to approximately CNY 254.72 million, driven by higher cash receipts from sales[50]. - The cash outflow for investing activities was CNY 270,932,444.52 in the first half of 2022, significantly higher than CNY 69,146,196.99 in the first half of 2021, indicating increased investment activity[145]. - The cash inflow from financing activities increased to CNY 306,620,000.00 in the first half of 2022, up from CNY 200,000,000.00 in the first half of 2021, marking a 53.3% increase[145]. Operational Performance - The chemical segment produced 273,700 tons of urea and sold 287,900 tons, while methanol production was 168,700 tons with sales of 163,000 tons[37]. - Urea sales volume increased by 1,100 tons year-on-year, with an average selling price rising by 748.02 yuan/ton[37]. - Methanol sales volume increased by 12,400 tons year-on-year, with an average selling price rising by 210.16 yuan/ton[37]. - The pharmaceutical segment generated an operating revenue of 53 million yuan, with a profit of -60 million yuan[37]. - The pharmaceutical manufacturing process is strictly regulated to comply with GMP guidelines, ensuring product quality throughout production[28]. - The company is focusing on developing the market for its unique medical insurance product, the heavy-leaf detoxification tincture, with a long-term cultivation plan[31]. Research and Development - The company increased R&D investment to 49.025 million yuan, accounting for 3.72% of Tongzi Chemical's revenue, and completed several projects that resulted in significant cost savings, including a 50% reduction in ammonia consumption for denitrification[39]. - Research and development expenses rose by 53.08% year-on-year to approximately CNY 56.38 million, reflecting increased investment in R&D activities[48]. - The company is enhancing its R&D capabilities to ensure a complete product structure in its pharmaceutical business[63]. - The company is advancing the R&D of several products, including Donepezil Hydrochloride Tablets and Tranexamic Acid Injection, which are currently in the approval process and are expected to enhance competitive advantages in bidding and hospital evaluations[42]. Environmental Compliance - The subsidiary Tongzi Chemical has installed online monitoring systems for wastewater and air emissions, ensuring all discharge indicators meet standards[72]. - In the first half of the year, Tongzi Chemical emitted 364.357 tons of sulfur dioxide, 206.443 tons of nitrogen oxides, and 26.860 tons of particulate matter, all within permitted limits[75]. - The wastewater treatment facility at Shengjitang Pharmaceutical has a daily processing capacity of 140 tons, effectively treating wastewater to meet discharge standards[76]. - The company has established a comprehensive environmental monitoring system to ensure compliance with environmental regulations[72]. - The company monitored wastewater discharge with a total volume of 5,492 tons in the first half of 2022, with COD at 0.064 tons and ammonia nitrogen at 0.0148 tons, both within regulatory limits[79]. Corporate Governance - The company has made changes in its board of directors, including the appointment of a new independent director[68]. - The company has committed to maintaining the independence of its financial operations, ensuring separate financial departments and accounting systems post-restructuring[99]. - The company guarantees that its senior management will not hold positions in related companies outside of their roles in the listed company, ensuring personnel independence[99]. - The company has established measures to ensure the independence of its operational management and internal structures[99]. Legal and Regulatory Matters - The company has not reported any major litigation or arbitration matters during the reporting period[104]. - The total amount involved in litigation cases reached CNY 6,646,608.4, with various companies owing amounts including CNY 2,464,782 and CNY 3,816,921 for unpaid goods and interest[106]. - The controlling shareholder, Guizhou Yuyang Trading Co., Ltd., received a public reprimand from the Shanghai Stock Exchange for failing to fulfill performance compensation commitments[108]. Market and Competitive Landscape - The company faces risks related to raw material coal supply due to national capacity reduction policies, leading to a long-term tight supply in the coal market[58]. - The price of raw coal has remained high, increasing production costs for the company, with significant impacts expected from changes in coal import volumes and domestic supply-demand dynamics[59]. - The domestic urea market is experiencing high prices, but a potential oversupply in the second half of the year may lead to price corrections[59].

Financial Performance - The company's operating revenue for Q1 2022 was ¥576,148,030.63, representing a year-on-year increase of 30.88%[4] - The net profit attributable to shareholders was -¥87,046,720.08, with a basic and diluted earnings per share of -¥0.0514[4] - Total operating revenue for Q1 2022 was CNY 576,148,030.63, an increase of 30.9% compared to CNY 440,200,269.71 in Q1 2021[15] - Net profit for Q1 2022 was a loss of CNY 87,634,392.15, compared to a profit of CNY 29,410,266.61 in Q1 2021[16] - The comprehensive income total for Q1 2022 was a loss of ¥14,299,272.58, compared to a loss of ¥8,217,388.69 in Q1 2021[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,782,384,729.91, an increase of 3.92% compared to the end of the previous year[5] - Total current assets as of March 31, 2022, amount to ¥1,715,563,547.67, an increase from ¥1,529,789,757.92 as of December 31, 2021[12] - Total liabilities as of March 31, 2022, are ¥1,700,801,394.51, compared to ¥1,432,117,778.16 at the end of 2021[13] - The total assets increased to ¥3,242,662,386.25 as of March 31, 2022, up from ¥3,173,899,518.09 at the end of December 2021, representing a growth of approximately 2.17%[19] - The total liabilities rose to ¥453,223,348.00, compared to ¥370,161,207.26 in the previous period, marking an increase of about 22.43%[21] Equity - The equity attributable to shareholders decreased by 2.78% to ¥3,077,250,152.86[5] - The total equity attributable to shareholders of the parent company decreased to CNY 3,077,250,152.86 from CNY 3,165,129,156.69 year-over-year[14] - The company's total equity decreased to ¥2,789,439,038.26 from ¥2,803,738,310.83, reflecting a decline of approximately 0.51%[21] Expenses - The company reported a significant increase in research and development expenses by 240.11%, attributed to increased investment in R&D[6] - Operating costs rose by 47.17%, primarily due to increased sales volume and higher raw material procurement costs[6] - The company experienced a 127.61% increase in management expenses, mainly due to maintenance costs and losses during repairs[6] - Research and development expenses increased to CNY 38,180,899.23 in Q1 2022, up from CNY 11,226,015.51 in Q1 2021, reflecting a growth of 239.5%[15] Cash Flow - Cash flow from operating activities showed a decrease, primarily due to increased cash payments for goods and services[6] - The company reported a net cash outflow from operating activities of CNY -19,436,613.11 in Q1 2022, compared to an inflow of CNY 114,553,375.80 in Q1 2021[17] - Cash flow from operating activities for Q1 2022 was ¥35,984,060.45, down from ¥76,107,045.23 in Q1 2021[26] - The cash and cash equivalents at the end of Q1 2022 were ¥7,410,240.54, significantly down from ¥42,522,196.83 at the end of Q1 2021[27] Shareholder Information - Total number of common shareholders at the end of the reporting period is 66,375[8] - Guizhou Yuyang Trading Co., Ltd. holds 447,733,356 shares, accounting for 26.44% of total shares[8] - The company has identified Guizhou Yuyang Trading Co., Ltd. and Guizhou Chitianhua Group Co., Ltd. as acting in concert among the top shareholders[9]

Financial Performance - The company's operating revenue for 2021 was CNY 2,181,369,746.32, representing a 13.21% increase compared to CNY 1,926,852,891.74 in 2020[21]. - The net profit attributable to shareholders was -CNY 51,868,730.39, a decrease from a profit of CNY 55,605,342.41 in the previous year[22]. - The cash flow from operating activities was CNY 276,666,953.35, showing a 4.58% increase from CNY 264,557,038.82 in 2020[22]. - The total assets at the end of 2021 were CNY 4,602,167,789.46, a decrease of 1.14% from CNY 4,655,407,666.13 at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 1.71% to CNY 3,165,129,156.69 from CNY 3,220,207,150.01 in 2020[22]. - The cumulative profit available for distribution to shareholders was -CNY 206,639.58 million, indicating no cash dividends or stock bonuses for 2021[5]. - The company reported a basic earnings per share of -0.0306 yuan, a decrease from 0.0328 yuan in 2020[23]. - The company achieved a total production of 585,500 tons of urea in 2021, representing a year-on-year increase of 5.13%[33]. - The company achieved operating revenue of 218,136.97 million RMB, with a net profit attributable to the parent company of -5,186.87 million RMB, and a net profit excluding non-recurring gains and losses of -5,722.22 million RMB[78]. Revenue and Sales - The total operating revenue for the first quarter was 440.2 million yuan, with a year-on-year increase of 71%[25]. - The total revenue for the second quarter reached 591.62 million yuan, marking a 12% increase from the first quarter[25]. - The company reported a total revenue of RMB 13,783.31 million, a decrease of 62.61% compared to the previous year[120]. - The revenue from Western medicine was RMB 11,844.65 million, reflecting a significant decline of 59.04% year-on-year[121]. - Urea sales revenue was CNY 1,185,490,529.36, with a gross margin of 23.64%, reflecting a decrease in profitability[84]. Market Conditions - The domestic urea market in 2021 experienced price fluctuations, with prices reaching historical highs due to supply-demand imbalances and inflation[41]. - Urea prices reached historical highs in the second and third quarters of 2021, driven by supply constraints and increased demand, despite a decline in demand in August due to export policy tightening[42]. - The average price of compound fertilizer in 2021 was 2,744 RMB/ton, with significant price increases observed throughout the year[48]. - The pharmaceutical industry is entering a low-profit era due to the normalization of centralized procurement, with average price reductions exceeding 50% for certain drugs[160]. - The company is experiencing a competitive landscape in the fertilizer industry, with traditional fertilizer market share declining and a need for increased energy and resource efficiency[157]. Research and Development - The company applied for 25 intellectual property rights in 2021, including 1 invention patent and 24 utility model patents, all of which received acceptance notifications[35]. - The company’s research and development expenses increased due to higher investment in R&D by the chemical segment, indicating a focus on innovation[81]. - The company reported a research and development investment of 215.44 million RMB, accounting for 7.47% of operating revenue[127]. - The company's R&D investment capitalized ratio is 9.33%, indicating a significant portion of R&D costs are recognized as intangible assets[127]. - The company is focusing on new product development and cost control to maintain profitability in a challenging regulatory environment[160]. Operational Challenges - The company faced non-operating fund occupation by controlling shareholders and related parties[7]. - The company is facing challenges in the pharmaceutical sector due to stricter regulations and policy changes affecting production and sales[87]. - The company is facing risks related to coal supply shortages and price increases, which significantly impact production costs due to high coal dependency[166]. - The implementation of "carbon peak" and "carbon neutrality" policies poses challenges for traditional chemical production companies, requiring increased investment in energy efficiency and carbon reduction[167]. Strategic Initiatives - The company has established a robust sales network across major cities in China, enhancing its market presence and brand recognition through various promotional strategies[67]. - The company is actively pursuing partnerships to leverage synergies and enhance its product portfolio[179]. - The company plans to implement a new compensation scheme for senior management starting January 1, 2022, as approved by the board[186]. - The company is exploring potential acquisitions to enhance its product portfolio and distribution channels[185]. - The company is committed to enhancing product quality management in response to stricter regulatory requirements and increased responsibilities for drug manufacturers[160]. Management and Governance - The total pre-tax remuneration for the chairman, Ding Linhong, was CNY 564,000[177]. - The total pre-tax remuneration for the vice chairman, Zhou Junsheng, was CNY 572,700[177]. - The company has established a comprehensive governance structure to ensure independence from its controlling shareholders, maintaining operational autonomy[173]. - Financial independence is upheld through a complete and compliant financial accounting system, with no shared banking arrangements with controlling entities[174]. - The company has implemented measures to prevent fund occupation by controlling shareholders, ensuring financial integrity and operational independence[173].

Financial Performance - The company's operating revenue for 2021 was CNY 2,181,369,746.32, representing a 13.21% increase compared to CNY 1,926,852,891.74 in 2020[21]. - The net profit attributable to shareholders was a loss of CNY 51,868,730.39, compared to a profit of CNY 55,605,342.41 in the previous year[22]. - The cash flow from operating activities was CNY 276,666,953.35, showing a 4.58% increase from CNY 264,557,038.82 in 2020[22]. - The total assets at the end of 2021 were CNY 4,602,167,789.46, a decrease of 1.14% from CNY 4,655,407,666.13 at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 1.71% to CNY 3,165,129,156.69 from CNY 3,220,207,150.01 in 2020[22]. - The cumulative undistributed profits as of December 31, 2021, were CNY -206,639.58 million, indicating no conditions for profit distribution[5]. - The company did not declare cash dividends or bonus shares for the year 2021 due to negative distributable profits[5]. - The company reported a basic earnings per share of -0.0306 CNY for 2021, a decrease from 0.0328 CNY in 2020[23]. - The company’s net profit attributable to shareholders was -5,186.87 million RMB, with a net profit excluding non-recurring items of -5,722.22 million RMB[78]. Operational Highlights - The total operating revenue for the fourth quarter was 526,307,352.98 CNY, with a year-over-year increase of 51% compared to the third quarter[25]. - The net profit attributable to shareholders for the fourth quarter was -170,561,532.5 CNY, a significant decline from 36,513,639.5 CNY in the third quarter[25]. - The company achieved a total operating revenue of 203,019.57 million CNY in its chemical business, reflecting a year-over-year increase of 31.53%[32]. - The average coal procurement price surged to 2200 CNY per ton in the fourth quarter, impacting the company's operational costs[33]. - The effective production time for the chemical business was 340 days in 2021, a decrease of 4.5% compared to 2020[33]. - The company produced 58.55 million tons of urea in 2021, representing a year-over-year increase of 5.13%[33]. - The company reported a cash flow from operating activities of 114,553,375 CNY in the first quarter of 2021[26]. - The company plans to enhance production management and optimize operational processes to mitigate external adverse impacts[33]. Market and Industry Trends - The domestic urea market in 2021 experienced price fluctuations, with prices reaching historical highs due to supply-demand mismatches and inflation factors[41]. - In 2021, the total production of urea in China was 53.699 million tons, a slight decrease of 0.06% compared to 2020[43]. - Urea prices reached historical highs in the second and third quarters of 2021, driven by supply constraints and increased demand, despite a decline in demand in August due to export policy tightening[42]. - The average price of compound fertilizer in 2021 was 2,744 RMB/ton, with significant price increases observed throughout the year[48]. - The production capacity of methanol in China was 96.74 million tons in 2021, reflecting a year-on-year growth of 3.54%[54]. - The actual methanol production in 2021 was 78.9995 million tons, an increase of 9.45% compared to 2020[54]. - The overall market for urea is influenced by both positive and negative factors, with global food security concerns likely to have a greater positive impact[48]. - The domestic methanol market experienced significant fluctuations, with prices reaching historical highs due to various market pressures, including high coal prices and supply constraints[53]. Research and Development - The company applied for 25 intellectual property rights in 2021, including 1 invention patent and 24 utility model patents, all of which received acceptance notices[35]. - The company’s research and development expenses increased by 32.02% to 95,625.80 million RMB, indicating a commitment to enhancing product development[81]. - Total R&D investment reached 97,907,255.58 CNY, which is 4.49% of operating revenue, with capitalized R&D accounting for 2.33%[93]. - The number of R&D personnel is 148, making up 12.63% of the total workforce[94]. - The company has made significant advancements in the development of drugs for various conditions, including diabetes and hypertension, with several projects in the final stages of research[123]. - The company is actively pursuing regulatory approvals for new products, with several applications currently under review by the National Medical Products Administration[125]. - The company has established a robust governance structure to ensure independence from its controlling shareholders, maintaining operational autonomy[173]. Strategic Initiatives - The company is focusing on new product development and technological advancements to meet evolving market demands[180]. - The company is exploring partnerships to expand its market reach and enhance product offerings[180]. - The company is investing heavily in R&D, with a budget allocation of 100 million yuan for the development of new pharmaceutical technologies[184]. - The company is actively expanding its presence in the internet healthcare sector, supported by government policies aimed at promoting telemedicine services[162]. - The company is committed to enhancing quality management and regulatory compliance in response to stricter oversight in the pharmaceutical industry[161]. - The company plans to produce 581,800 tons of urea, 357,500 tons of methanol, and 24.53 million boxes (bottles, units) of pharmaceuticals in 2022, with an expected revenue of 2,521.87 million yuan and a projected total profit of -191.42 million yuan[166]. Corporate Governance and Management - The total pre-tax remuneration for the chairman, Ding Linhong, was CNY 564,000[178]. - The total pre-tax remuneration for the vice chairman, Zhou Junsheng, was CNY 572,700[178]. - The total pre-tax remuneration for the independent director, Shi Yucheng, was CNY 100,000[178]. - The total pre-tax remuneration for the independent director, Liu Jian, was CNY 100,000[178]. - The total pre-tax remuneration for the independent director, Wang Pu, was CNY 100,000[178]. - The total pre-tax remuneration for the supervisor, Dai Xuanzhong, was CNY 262,300[178]. - The total pre-tax remuneration for the board secretary, Xian Zhenghong, was CNY 402,700[178]. - The total pre-tax remuneration for the financial director, Wu Huan, was CNY 147,000[178]. - The total pre-tax remuneration for the deputy general manager, Chen Honglin, was CNY 367,400[178]. - The total pre-tax remuneration for the deputy general manager, Yang Yang, was CNY 0[178]. - The company has not faced any penalties from securities regulatory agencies in the past three years[189]. - The total number of employees in the parent company is 66, while the main subsidiaries employ 1,161, resulting in a total of 1,227 employees[200].